Corrections to “Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy”

Ann Oncol 2017; 28: 2707–2714 (doi: 10.1093/annonc/mdx414) In the original article, the funding information was omitted. It should have read as follows: This work was supported in part by a Career Development Award from the University of Colorado SPORE in Lung grant (#P50 058187) from the National Cancer Institute. The original article has been corrected online. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapyAnnals of OncologyVol. 28Issue 11PreviewResponse Evaluation Criteria in Solid Tumors (RECIST) permits rapid evaluation of new therapeutic strategies in cancer. However, RECIST does not capture the heterogeneity of response in highly active therapies. Depth of tumor response may provide a more granular view of response. We explored the association between, depth of response (DepOR), with overall survival (OS) and progression-free survival (PFS) for patients with NSCLC being treated with an ALK inhibitor (ALKi) or an anti-PD-1 antibody (Ab). Full-Text PDF Open Archive